Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AEZS-108 shows anti-tumor activity and is
tolerated in patients with gynecological tumors (ovarian / endometrial cancer) that have been
shown to express receptors for the luteinizing hormone releasing hormone (LHRH)